Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Inclusion Criteria: * Pathologically confirmed, initially treated, surgically resectable head and neck squamous cell carcinoma. * Clinical stage III to IVB (AJCC 8th edition), except HPV-positive oropharyngeal cancer * Following multidisciplinary discussions involving otolaryngologists and radiation oncologists, the assessment concluded that the tumor is resectable or marginally resectable and suitable for preoperative SBRT * Karnofsky Performance Status score ≥ 70 * Ages 18 to 70 * The primary organ functions meet the test requirements * Patients participate voluntarily and sign informed consent forms Exclusion Criteria: * Patients previously treated with head and neck surgery were excluded from diagnostic biopsies of primary and regional lymph nodes * Previous chemotherapy for any reason, or radiotherapy in the head and neck area, or molecular targeted drug therapy; Previously received anti-PD-1, anti-PD-L1, anti-PD-L2 and other drugs or drugs acting on another irritating or co-inhibitory T cell receptor (such as CTLA-4, OX 40, CD137) treatment, or cell biotherapy * Pregnant or lactating women * Have had or co-had other malignancies * The patient also has a serious, uncontrolled illness * Heart, brain, lung and other important organ function abnormal. Patients with hypertension (systolic blood pressure \>140 mmHg, diastolic blood pressure \>90 mmHg) who cannot be reduced to the normal range by antihypertensive drugs have grade I or above myocardial ischemia or myocardial…